Skip to main content
SpringerLink
Log in

Androgen Replacement Therapy in Hypogonadal Men

  • Chapter
  • First Online:
Male Hypogonadism

Part of the book series: Contemporary Endocrinology ((COE))

  • 1492 Accesses

Abstract

Androgen replacement therapy should be considered for all hypogonadal men with persistent low serum testosterone levels and symptoms of testosterone deficiency. Before commencement of replacement, contraindications to androgen treatment should be identified. In hypogonadal men, androgens improve sexual function, energy and mood, increase muscle mass and strength, as well as bone mineral density. Androgen therapy can be tailored to each patient’s needs and preferences. There are many new androgen delivery systems introduced in the past few years and many more are in development. Selective androgen receptor modulators may have the potential of optimizing beneficial effects while minimizing potential adverse effects. In older men, monitoring of prostate dysfunction and red cell indexes is necessary and important. With care, androgens can be used efficaciously and with minimal potential side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Int Med. 2013;173(15):1465–6.

    Article  Google Scholar 

  2. Nguyen CP, Hirsch MS, Moeny D, Kaul S, Mohamoud M, Joffe HV. Testosterone and “age-related hypogonadism”–FDA concerns. N Engl J Med. 2015;373(8):689–91.

    Article  PubMed  Google Scholar 

  3. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.

    Article  CAS  PubMed  Google Scholar 

  4. Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100(3):1146–55.

    Article  CAS  PubMed  Google Scholar 

  5. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.

    Article  CAS  PubMed  Google Scholar 

  6. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49(8):1381–95.

    Article  CAS  PubMed  Google Scholar 

  7. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine society position statement. J Clin Endocrinol Metab. 2007;92(2):405–13.

    Article  CAS  PubMed  Google Scholar 

  8. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89(2):534–43.

    Article  CAS  PubMed  Google Scholar 

  9. Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol. 2010.

    Google Scholar 

  10. Vesper HW, Botelho JC, Shacklady C, Smith A, Myers GL. CDC project on standardizing steroid hormone measurements. Steroids. 2008;73(13):1286–92.

    Article  CAS  PubMed  Google Scholar 

  11. Vesper HW, Thienpont LM. Traceability in laboratory medicine. Clin Chem. 2009;55(6):1067–75.

    Article  CAS  PubMed  Google Scholar 

  12. Steinberger E, Ayala C, Hsi B, Smith KD, Rodriguez-Rigau LJ, Weidman ER, et al. Utilization of commercial laboratory results in management of hyperandrogenism in women. Endocr Pract Official J Am Coll Endocrinol Am Assoc Clin Endocrinol. 1998;4(1):1–10.

    CAS  Google Scholar 

  13. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72.

    Article  CAS  PubMed  Google Scholar 

  14. O’Connor S, Baker HW, Dulmanis A, Hudson B. The measurement of sex steroid binding globulin by differential ammonium sulphate precipitation. J Steroid Biochem. 1973;4(4):331–9.

    Article  PubMed  Google Scholar 

  15. Cumming DC, Wall SR. Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism. J Clin Endocrinol Metab. 1985;61(5):873–6.

    Article  CAS  PubMed  Google Scholar 

  16. Sinha-Hikim I, Arver S, Beall G, Shen R, Guerrero M, Sattler F, et al. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1998;83(4):1312–8.

    CAS  PubMed  Google Scholar 

  17. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.

    Article  CAS  PubMed  Google Scholar 

  18. Zakharov MN, Bhasin S, Travison TG, Xue R, Ulloor J, Vasan RS, et al. A multi-step, dynamic allosteric model of testosterone’s binding to sex hormone binding globulin. Mol Cell Endocrinol. 2015;399:190–200.

    Article  CAS  PubMed  Google Scholar 

  19. Ohlsson C, Wallaschofski H, Lunetta KL, Stolk L, Perry JR, Koster A, et al. Genetic determinants of serum testosterone concentrations in men. PLoS Genet. 2011;7(10):e1002313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Vermeulen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab. 1991;73(2):221–4.

    Article  CAS  PubMed  Google Scholar 

  21. Vermeulen A. Decreased androgen levels and obesity in men. Ann Med. 1996;28(1):13–5.

    Article  CAS  PubMed  Google Scholar 

  22. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab. 1977;45(6):1211–9.

    Article  CAS  PubMed  Google Scholar 

  23. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16(6):801–10.

    Article  CAS  PubMed  Google Scholar 

  24. de Ronde W, van der Schouw YT, Pols HA, Gooren LJ, Muller M, Grobbee DE, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem. 2006;52(9):1777–84.

    Article  PubMed  CAS  Google Scholar 

  25. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol. 2010;73:382–8.

    Article  CAS  Google Scholar 

  26. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem. 2009;46(Pt 2):137–43.

    Article  CAS  PubMed  Google Scholar 

  27. Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab. 1997;82(6):2014–5.

    Article  CAS  PubMed  Google Scholar 

  28. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clin Chem. 1998;44(10):2178–82.

    CAS  PubMed  Google Scholar 

  29. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab. 2004;89(2):525–33.

    Article  CAS  PubMed  Google Scholar 

  30. Khosla S, Riggs BL. Androgens, estrogens, and bone turnover in men. J Clin Endocrinol Metab. 2003;88(5):2352–3.

    Article  CAS  PubMed  Google Scholar 

  31. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94(12):4785–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Liu PY, Caterson ID, Grunstein RR, Handelsman DJ. Androgens, obesity, and sleep-disordered breathing in men. Endocrinol Metab Clin North Am. 2007;36(2):349–63.

    Article  CAS  PubMed  Google Scholar 

  34. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13(4):297–304.

    CAS  PubMed  Google Scholar 

  35. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979;48(6):955–8.

    Article  CAS  PubMed  Google Scholar 

  36. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol. 1981;14(1):49–61.

    Article  CAS  Google Scholar 

  37. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3654–62.

    CAS  PubMed  Google Scholar 

  38. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–53.

    CAS  PubMed  Google Scholar 

  39. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997;82(11):3793–6.

    Article  CAS  PubMed  Google Scholar 

  40. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647–53.

    CAS  PubMed  Google Scholar 

  41. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840–56.

    Article  CAS  PubMed  Google Scholar 

  42. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diab Care. 2011;34(4):828–37.

    Article  CAS  Google Scholar 

  43. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284–93.

    Article  CAS  PubMed  Google Scholar 

  45. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81.

    Article  CAS  PubMed  Google Scholar 

  46. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–81.

    CAS  PubMed  Google Scholar 

  47. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–43.

    Article  CAS  PubMed  Google Scholar 

  48. Dabbs JM Jr. Salivary testosterone measurements in behavioral studies. Ann N Y Acad Sci. 1993;694:177–83.

    Article  CAS  PubMed  Google Scholar 

  49. O’Connor DB, Archer J, Hair WM, Wu FC. Activational effects of testosterone on cognitive function in men. Neuropsychologia. 2001;39(13):1385–94.

    Article  PubMed  Google Scholar 

  50. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79(2):561–7.

    CAS  PubMed  Google Scholar 

  51. Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab. 1992;75(6):1503–7.

    CAS  PubMed  Google Scholar 

  52. Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3556–62.

    CAS  PubMed  Google Scholar 

  53. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3578–83.

    CAS  PubMed  Google Scholar 

  54. Tong SF, Ng CJ, Lee BC, Lee VK, Khoo EM, Lee EG, et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian J Androl. 2012;14(4):604–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Pope HG Jr, Amiaz R, Brennan BP, Orr G, Weiser M, Kelly JF, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol. 2010;30(2):126–34.

    Article  CAS  PubMed  Google Scholar 

  56. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav. 1998;33(2):85–94.

    Article  CAS  PubMed  Google Scholar 

  57. Boone KB, Swerdloff RS, Miller BL, Geschwind DH, Razani J, Lee A, et al. Neuropsychological profiles of adults with Klinefelter syndrome. J Int Neuropsychol Soc. 2001;7(4):446–56.

    Article  CAS  PubMed  Google Scholar 

  58. Patwardhan AJ, Eliez S, Bender B, Linden MG, Reiss AL. Brain morphology in Klinefelter syndrome: extra X chromosome and testosterone supplementation. Neurology. 2000;54(12):2218–23.

    Article  CAS  PubMed  Google Scholar 

  59. Cherrier MM, Anawalt BD, Herbst KL, Amory JK, Craft S, Matsumoto AM, et al. Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. J Clin Endocrinol Metab. 2002;87(7):3090–6.

    Article  CAS  PubMed  Google Scholar 

  60. Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci. 2000;12(3):407–14.

    Article  CAS  PubMed  Google Scholar 

  61. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108(2):325–32.

    Article  CAS  PubMed  Google Scholar 

  62. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57(5):M321–5.

    Article  PubMed  Google Scholar 

  63. Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002;50(4):707–12.

    Article  PubMed  Google Scholar 

  64. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J Bone Miner Res. 1997;12(11):1833–43.

    Article  CAS  PubMed  Google Scholar 

  65. Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266–74.

    CAS  PubMed  Google Scholar 

  66. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689–98.

    CAS  PubMed  Google Scholar 

  67. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056–61.

    Article  CAS  PubMed  Google Scholar 

  68. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337(2):91–5.

    Article  CAS  PubMed  Google Scholar 

  69. Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86(8):3555–61.

    Article  CAS  PubMed  Google Scholar 

  70. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, Mavilia C, Del MF, et al. Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. J Clin Endocrinol Metab. 2004;89(4):1808–16.

    Article  CAS  PubMed  Google Scholar 

  71. Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016;126(3):1114–25.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989;86(3):854–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Cawthon PM, Schousboe JT, Harrison SL, Ensrud KE, Black D, Cauley JA, et al. Sex hormones, sex hormone binding globulin, and vertebral fractures in older men. Bone. 2016;84:271–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81(12):4358–65.

    CAS  PubMed  Google Scholar 

  75. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82(8):2386–90.

    Article  CAS  PubMed  Google Scholar 

  76. Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res. 2000;26(2):153–68.

    Article  CAS  PubMed  Google Scholar 

  77. Tenover JL. Male senescence. In: Wang C, editor. Male reproductive function. Boston: Kluwer Academic Publishers; 1999. p. 139–56.

    Chapter  Google Scholar 

  78. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670–7.

    CAS  PubMed  Google Scholar 

  79. Ishizaka K, Suzuki M, Kageyama Y, Kihara K, Yoshida K. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. Asian J Androl. 2002;4(2):117–21.

    CAS  PubMed  Google Scholar 

  80. Medras M, Jankowska EA, Rogucka E. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotrophic hypogonadism. Andrologia. 2001;33(1):47–52.

    Article  CAS  PubMed  Google Scholar 

  81. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–43.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280–93.

    Article  CAS  PubMed  Google Scholar 

  83. Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al. THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99–116.

    Article  CAS  PubMed  Google Scholar 

  84. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3469–75.

    CAS  PubMed  Google Scholar 

  85. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283(1):E154–64.

    Article  CAS  PubMed  Google Scholar 

  86. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82(2):407–13.

    CAS  PubMed  Google Scholar 

  87. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3):1502–10.

    Article  CAS  PubMed  Google Scholar 

  88. Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999;22(4):261–5.

    Article  CAS  PubMed  Google Scholar 

  89. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.

    Article  CAS  PubMed  Google Scholar 

  90. Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95.

    Article  CAS  PubMed  Google Scholar 

  91. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.

    Article  CAS  PubMed  Google Scholar 

  92. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167(4):531–41.

    Article  CAS  PubMed  Google Scholar 

  93. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Vanttinen T, Blomqvist M, Hakkinen K. Development of body composition, hormone profile, physical fitness, general perceptual motor skills, soccer skills and on-the-ball performance in soccer-specific laboratory test among adolescent soccer players. J Sports Sci Med. 2010;9(4):547–56.

    PubMed  PubMed Central  Google Scholar 

  95. Frederiksen L, Hojlund K, Hougaard DM, Mosbech TH, Larsen R, Flyvbjerg A, et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. European journal of endocrinology/ European Federation of Endocrine Societies. 2012;166(3):469–76.

    Article  CAS  Google Scholar 

  96. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest. 2010;33(11):776–83.

    Article  CAS  PubMed  Google Scholar 

  97. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16(12):991–7.

    CAS  PubMed  Google Scholar 

  98. Neto WK, Gama EF, Rocha LY, Ramos CC, Taets W, Scapini KB, et al. Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies. Age (Dordr). 2015;37(1):9742.

    Article  PubMed  CAS  Google Scholar 

  99. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes Care. 2016;39(1):82–91.

    Article  PubMed  Google Scholar 

  100. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73(5):602–12.

    Article  CAS  PubMed  Google Scholar 

  101. Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37(8):2098–107.

    Article  CAS  PubMed  Google Scholar 

  102. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–33.

    Article  CAS  PubMed  Google Scholar 

  103. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European journal of endocrinology/ European Federation of Endocrine Societies. 2006;154(6):899–906.

    Article  CAS  Google Scholar 

  104. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014;2014:527470.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341–53.

    Article  CAS  PubMed  Google Scholar 

  106. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. The journal of sexual medicine. 2010;7(10):3495–503.

    Article  CAS  PubMed  Google Scholar 

  107. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–8.

    Article  CAS  PubMed  Google Scholar 

  108. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79(2):561–7.

    CAS  PubMed  Google Scholar 

  110. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol. 1997;47(6):727–37.

    Article  CAS  Google Scholar 

  111. Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab. 2001;86(3):1026–33.

    CAS  PubMed  Google Scholar 

  112. Friedl KE, Hannan CJ Jr, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990;39(1):69–74.

    Article  CAS  PubMed  Google Scholar 

  113. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.

    Article  CAS  PubMed  Google Scholar 

  114. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87(1):136–43.

    Article  CAS  PubMed  Google Scholar 

  115. Arora S, Patra SK, Saini R. HDL-A molecule with a multi-faceted role in coronary artery disease. Clinica chimica acta; international journal of clinical chemistry. 2015;452:66–81.

    Article  PubMed  CAS  Google Scholar 

  116. Barter PJ, Rye KA. Targeting High-Density Lipoproteins to Reduce Cardiovascular Risk: what Is the Evidence? Clinical therapeutics. 2015.

    Google Scholar 

  117. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14(5):701–6.

    Article  CAS  PubMed  Google Scholar 

  118. Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol. 1998;63(2):161–4.

    Article  CAS  PubMed  Google Scholar 

  119. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75.

    Article  CAS  PubMed  Google Scholar 

  120. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694–701.

    Article  CAS  PubMed  Google Scholar 

  121. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European journal of endocrinology/ European Federation of Endocrine Societies. 2011;165(5):687–701.

    Article  CAS  Google Scholar 

  122. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 1988;78(3):539–45.

    CAS  PubMed  Google Scholar 

  123. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab. 1997;82(2):682–5.

    CAS  PubMed  Google Scholar 

  124. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660–5.

    Article  CAS  PubMed  Google Scholar 

  125. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1977;39(11):1217–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J. 1993;106(6):415–8.

    CAS  PubMed  Google Scholar 

  127. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21(11):890–4.

    Article  CAS  PubMed  Google Scholar 

  128. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99(13):1666–70.

    Article  CAS  PubMed  Google Scholar 

  129. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100(16):1690–6.

    Article  CAS  PubMed  Google Scholar 

  130. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J. 2002;143(2):249–56.

    Article  CAS  PubMed  Google Scholar 

  131. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Vigen R, O’Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.

    Article  CAS  PubMed  Google Scholar 

  133. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050–8.

    Article  CAS  PubMed  Google Scholar 

  134. Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth WT Jr, Kizer JR, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9(1):e85805.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  137. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327–51.

    Article  CAS  PubMed  Google Scholar 

  139. Corona GG, Rastrelli G, Maseroli E, Sforza A, Maggi M. Testosterone replacement therapy and cardiovascular risk: a review. World J Men’s Health. 2015;33(3):130–42.

    Article  Google Scholar 

  140. Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf). 2016.

    Google Scholar 

  141. Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR. American association of clinical endocrinologists and American college of endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr Pract Official J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2015;21(9):1066–73.

    Google Scholar 

  142. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol. 1994;40(3):341–9.

    Article  CAS  Google Scholar 

  143. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49(2):191–6.

    Article  CAS  PubMed  Google Scholar 

  144. Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab. 2013;98(5):1891–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Del Fabbro E, Garcia JM, Dev R, Hui D, Williams J, Engineer D, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer. 2013;21(9):2599–607.

    Article  PubMed  Google Scholar 

  146. Tan WS, Low WY, Ng CJ, Tan WK, Tong SF, Ho C, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int. 2013;111(7):1130–40.

    Article  CAS  PubMed  Google Scholar 

  147. Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016.

    Google Scholar 

  148. Handelsman DJ. The safety of androgens: prostate and cardiovascular disease. In: Wang C, editor. Male reproductive function. Boston: Kluwer Academic Publishers; 1999. p. 173–89.

    Chapter  Google Scholar 

  149. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.

    Article  CAS  PubMed  Google Scholar 

  150. Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol. 2011;186(1):191–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114(11):2236–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Bar C, Huber N, Beier F, Blasco MA. Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres. Haematologica. 2015;100(10):1267–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Townsley DM, Dumitriu B, Liu D, Biancotto A, Weinstein B, Chen C, et al. Danazol treatment for telomere diseases. N Engl J Med. 2016;374(20):1922–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Rencricca NJ, Solomon J, Fimian WJ Jr, Howard D, Rizzoli V, Stohlman F Jr. The effect of testosterone on erythropoiesis. Scand J Haematol. 1969;6(6):431–6.

    Article  CAS  PubMed  Google Scholar 

  155. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725–35.

    Article  CAS  PubMed  Google Scholar 

  156. Guo W, Bachman E, Li M, Roy CN, Blusztajn J, Wong S, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. 2013;12(2):280–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678–88.

    Article  CAS  PubMed  Google Scholar 

  158. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914–9.

    Article  CAS  PubMed  Google Scholar 

  159. Delorimier AA, Gordan GS, Lowe RC, Carbone JV. Methyltestosterone, related steroids, and liver function. Arch Intern Med. 1965;116:289–94.

    Article  CAS  PubMed  Google Scholar 

  160. Nadell J, Kosek J. Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med. 1977;101(8):405–10.

    CAS  PubMed  Google Scholar 

  161. Stout M, Tew GA, Doll H, Zwierska I, Woodroofe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J. 2012;164(6):893–901.

    Article  CAS  PubMed  Google Scholar 

  162. Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol. 1985;22(6):713–21.

    Article  CAS  Google Scholar 

  163. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412–20.

    Article  CAS  PubMed  Google Scholar 

  164. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51(6):1335–9.

    Article  CAS  PubMed  Google Scholar 

  165. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982;37(3):425–30.

    Article  CAS  PubMed  Google Scholar 

  166. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl. 1998;19(6):761–8.

    CAS  PubMed  Google Scholar 

  167. Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol Eur Fed Endocr Soc. 1999;140(5):414–9.

    Article  CAS  Google Scholar 

  168. Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol. 1999;51(6):757–63.

    Article  CAS  Google Scholar 

  169. Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R, Swerdloff RS, et al. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. J Urol. 2008;180(6):2307–13.

    Article  PubMed  Google Scholar 

  170. Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl. 2010;31(5):457–65.

    Article  CAS  PubMed  Google Scholar 

  171. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78.

    CAS  PubMed  Google Scholar 

  172. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12(1):5–12.

    Article  PubMed  Google Scholar 

  173. Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab. 1992;74(1):75–83.

    CAS  PubMed  Google Scholar 

  174. Amory JK, Anawalt BD, Blaskovich PD, Gilchriest J, Nuwayser ES, Matsumoto AM. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl. 2002;23(1):84–91.

    Article  CAS  PubMed  Google Scholar 

  175. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy. 2003;23(3):319–25.

    Article  CAS  PubMed  Google Scholar 

  176. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. The effect of food composition on serum testosterone levels after oral administration of Andriol testocaps. Clin Endocrinol. 2007;66(4):579–85.

    CAS  Google Scholar 

  177. Nieschlag E, Mauss J, Coert A, Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh). 1975;79(2):366–74.

    CAS  PubMed  Google Scholar 

  178. Schurmeyer T, Wickings EJ, Freischem CW, Nieschlag E. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol (Copenh). 1983;102(3):456–62.

    CAS  PubMed  Google Scholar 

  179. Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol Eur Fed Endocr Soc. 2009;160(5):821–31.

    Article  CAS  Google Scholar 

  180. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52.

    Article  CAS  PubMed  Google Scholar 

  181. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 1994;15(3):212–5.

    CAS  PubMed  Google Scholar 

  182. Yin A, Alfadhli E, Htun M, Dudley R, Faulkner S, Hull L, et al. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men. J Androl. 2012;33(6):1282–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Yin AY, Htun M, Swerdloff RS, Diaz-Arjonilla M, Dudley RE, Faulkner S, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. J Androl. 2012;33(2):190–201.

    Article  CAS  PubMed  Google Scholar 

  184. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA. 1989;261(17):2525–30.

    Article  CAS  PubMed  Google Scholar 

  185. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab. 1989;68(2):369–73.

    Article  CAS  PubMed  Google Scholar 

  186. Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, et al. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J Clin Pharmacol. 1996;36(8):732–9.

    Article  CAS  PubMed  Google Scholar 

  187. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site—a clinical research center study. J Clin Endocrinol Metab. 1996;81(5):1832–40.

    CAS  PubMed  Google Scholar 

  188. Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 1992;74(3):623–8.

    CAS  PubMed  Google Scholar 

  189. Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Jick SS, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500–10.

    CAS  PubMed  Google Scholar 

  191. Swerdloff RS, Pak Y, Wang C, Liu PY, Bhasin S, Gill TM, et al. Serum testosterone (T) level variability in T gel-treated older hypogonadal men: treatment monitoring implications. J Clin Endocrinol Metab. 2015;100(9):3280–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Muram D, Ni X. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men. Curr Med Res Opin. 2015;1–24.

    Google Scholar 

  193. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol. 2001;54(6):739–50.

    Article  Google Scholar 

  194. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–98.

    Article  CAS  PubMed  Google Scholar 

  195. Satonin DK, Ni X, Mitchell MI, Joly H, Muram D, Small DS. Amount of testosterone on laundered clothing after use of testosterone topical 2% solution by healthy male volunteers. J Sex Med. 2016;13(2):187–93.

    Article  PubMed  Google Scholar 

  196. Muram D, Melby T. Alles Kingshill E. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men. Curr Med Res Opin. 2012;28(5):761–6.

    Article  CAS  PubMed  Google Scholar 

  197. Schaison GNK, Couzinet B. Percutaneous dihydrotestosterone (DHT) treatment. In: Nieschlag EBH, editor. Testosterone: action deficiency, substitution. Berlin: Springer; 1990. p. 155–64.

    Chapter  Google Scholar 

  198. de Lignieres B. Transdermal dihydrotestosterone treatment of ‘andropause’. Ann Med. 1993;25(3):235–41.

    Article  PubMed  Google Scholar 

  199. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87(4):1467–72.

    Article  CAS  PubMed  Google Scholar 

  200. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001;86(9):4078–88.

    Article  CAS  PubMed  Google Scholar 

  201. Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men—a clinical research center study. J Clin Endocrinol Metab. 1998;83(8):2749–57.

    CAS  PubMed  Google Scholar 

  202. Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab. 2002;87(4):1462–6.

    Article  CAS  PubMed  Google Scholar 

  203. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ, et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med. 2010;153(10):621–32.

    Article  PubMed  Google Scholar 

  204. Rogol AD, Tkachenko N, Bryson N. NatestoTM, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016;4(1):46–54.

    Article  CAS  PubMed  Google Scholar 

  205. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004;89(8):3821–9.

    Article  CAS  PubMed  Google Scholar 

  206. Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012;110(2):162–9.

    Article  CAS  PubMed  Google Scholar 

  207. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990;71(1):216–22.

    Article  CAS  PubMed  Google Scholar 

  208. Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol. 1997;47(3):311–6.

    Article  CAS  Google Scholar 

  209. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ. Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol. 1999;51(4):469–71.

    Article  CAS  Google Scholar 

  210. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(12):3597–617.

    Article  CAS  PubMed  Google Scholar 

  211. Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab. 1998;83(12):4212–9.

    CAS  PubMed  Google Scholar 

  212. Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology. 1992;130(6):3677–83.

    CAS  PubMed  Google Scholar 

  213. Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7α-Methyl-19-Nortestosterone in hypogonadal men. J Clin Endocrinol Metab. 2003;88(6):2784–93.

    Article  CAS  PubMed  Google Scholar 

  214. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88(11):5232–9.

    Article  CAS  Google Scholar 

  215. Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006;147(6):3016–26.

    Article  CAS  PubMed  Google Scholar 

  216. Surampudi P, Page ST, Swerdloff RS, Nya-Ngatchou JJ, Liu PY, Amory JK, et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology. 2014;2(4):579–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  217. Edwards JP, Zhi L, Pooley CL, Tegley CM, West SJ, Wang MW, et al. Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. J Med Chem. 1998;41(15):2779–85.

    Article  CAS  PubMed  Google Scholar 

  218. Hamann LG, Higuchi RI, Zhi L, Edwards JP, Wang XN, Marschke KB, et al. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J Med Chem. 1998;41(4):623–39.

    Article  CAS  PubMed  Google Scholar 

  219. Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345–51.

    Article  PubMed  Google Scholar 

  220. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  221. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153–61.

    Article  PubMed  PubMed Central  Google Scholar 

  222. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500–10.

    CAS  PubMed  Google Scholar 

  223. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Ferti Steril. 1982;37(3):425–30.

    Article  CAS  Google Scholar 

  224. Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth WT Jr, Kizer JR, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  225. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050–8.

    Article  CAS  PubMed  Google Scholar 

  226. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–33.

    Article  CAS  PubMed  Google Scholar 

  227. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–7.

    Article  PubMed  Google Scholar 

  228. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29–39.

    Article  CAS  PubMed  Google Scholar 

  229. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.

    Article  CAS  PubMed  Google Scholar 

  230. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012;5(3):315–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by UCLA CTSI Grant UL1TR000124 to Los Angeles Biomedical Research Institute and Harbor UCLA Medical Center (CW) and NICHD Contract HHSN27520130024I (RSS and CW) and the Baltic American Freedom Foundation Research Scholar Program (JC).

Author information

Authors and Affiliations

  1. Department of Endocrinology, Lithuanian University of Health Sciences, 2 Eiveniu St., 50009, Kaunas, Lithuania

    Jonas Čeponis MD, PhD

  2. Harbor UCLA Medical Center Los Angeles, Biomedical Research Institute, 1124 W. Carson St., Torrance, CA, 905025, USA

    Ronald S. Swerdloff MD

  3. Harbor UCLA Medical Center and Los Angeles Biomedical Research Institute, UCLA Clinical and Translational Science Institute, 1000 W. Carson St., Torrance, CA, 90509, USA

    Christina Wang MD

Authors
  1. Jonas Čeponis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald S. Swerdloff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christina Wang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Wang MD .

Editor information

Editors and Affiliations

  1. Department of Medicine, Endocrinology, D, University of Louisville Health Sciences, Louisville, USA

    Stephen J. Winters

  2. Department of Surgery and Cancer, Imperial College London, London, United Kingdom

    Ilpo T. Huhtaniemi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Čeponis, J., Swerdloff, R.S., Wang, C. (2017). Androgen Replacement Therapy in Hypogonadal Men. In: Winters, S., Huhtaniemi, I. (eds) Male Hypogonadism. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-53298-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53298-1_18

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-53296-7

  • Online ISBN: 978-3-319-53298-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation